Prestige BioPharma to Establish Vaccine Production Center... Targeting Completion Within the Year

[Asia Economy Reporter Chunhee Lee] Prestige BioPharma, a pharmaceutical company specializing in antibody drug development, is planning to establish a vaccine production center for COVID-19 and other vaccines.

Prestige BioPharma announced on the 8th that it will utilize 2,000㎡ of the site of its affiliate Prestige Biologics' second factory to build a vaccine production center with a total floor area of approximately 8,500㎡ within this year.

The vaccine production center aims for a global production scale of up to 100,000 liters. It plans to proactively respond to the production of vaccines not only for COVID-19 but also for various viral infectious diseases that may emerge in the future. Prestige BioPharma intends to start construction within this month and complete the building and production system validation within this year.

Park Soyeon, CEO of Prestige BioPharma, said, "Based on the establishment of a global-scale vaccine production center, we expect to create new revenue streams through vaccine research, development, and production businesses, as well as contribute to proactive infectious disease response."